Athersys, Inc. (ATHX)

     
Company Address:
3201 Carnegie Ave
Cleveland, Ohio 44115-2634
T:  216-431-9900
F:  216-361-9495
info@athersys.com
 
CIK:  0001368148
 
Athersys, Inc. fundamental goals are to create safer and more effective new therapies that can address significant unmet medical needs and to generate substantial value for our shareholders in the process.  We are committed to developing a portfolio of product development opportunities that we believe have the potential to be safer, more effective products than the current standard of care or other products in development that we are aware of, and that may have other advantages, such as superior scalability or ease of administration. By applying our distinctive technologies and capabilities, and by utilizing certain approaches to minimize development risk and costs, we believe that we achieve our goals while also being cost effective.
 
Management:  http://www.athersys.com/management.cfm?s=about
 
Clinical Programs:   http://www.athersys.com/clinicalPrograms.cfm
 
Recent News: 
http://finance.yahoo.com/q/h?s=ODP+Headlines
 
SEC Filings:  http://www.sec.gov/edgar/searchedgar/companysearch.html
 
Share Structure:  See SEC filings
 
Transfer Agent:
Computershare
250 Royall Street
Canton, MA 02021
T:  781-575-2598
F:  781-575-4647
 
Investor Relations:
info@athersys.com
 
   

 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp